Development of the Brussels Infant and Toddler Stool Scale ('BITSS'): protocol of the study

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Vandenplas Y
  • Szajewska H
  • Benninga M
  • Di Lorenzo C
  • Dupont C
  • Faure C
  • Miqdadi M
  • Osatakul S
  • Saps M
  • Shamir R
  • Staiano A
  • BITSS Study Group

Grups d'Investigació

Abstract

Introduction: The Bristol Stool Form Scale (BSS) which consists of 7 photographs of different stool forms allows assessment of stool consistency (scale 1 for hard lumps to scale 7 for watery stools), in an objective manner in adults. The BSS is also sometimes used to characterise the stools of infants and young children. Despite its use, there is general agreement among paediatric gastroenterologists that the BSS is not adequate to be used in infants and young children who wear diapers; thus, a new scale specifically designed for this population is needed. Our aim is to develop a paediatric stool scale, the Brussels Infant and Toddler Stool Scale (`BITSS'), and to evaluate the interobserver agreement of stool assessment with the BITSS between the patient's parent and healthcare providers (physicians and nurses). Methods and analysis: This study has two phases. In the first phase, 11 key-opinion leaders in the field of paediatric gastroenterology representing different areas of the world selected seven coloured photographs of infants and/or young children wearing diapers to match the original descriptors of the BSS. The selected photographs were used to create a new scale in which the drawings of stools of the BSS were replaced by infant/toddlers stool photographs. In phase II, we aim at demonstrating that parents, nurses and primary healthcare physicians interpret the stool-pictures of the BITSS with a high degree of consensus and that the agreement is independent of whether it is a parent or a healthcare provider. Interobserver variability of stool assessment with the BITSS between the patient's parent and healthcare providers will be assessed. Ethics and dissemination: The study will be approved by the Ethics Committee of the participating centres. The findings of this study will be submitted to a peer-reviewed journal. Abstracts will be submitted to national and international conferences.

Dades de la publicació

ISSN/ISSNe:
2044-6055, 2044-6055

BMJ Open  BMJ PUBLISHING GROUP

Tipus:
Article
Pàgines:
-
PubMed:
28360250
Factor d'Impacte:
1,372 SCImago
Quartil:
Q1 SCImago

Cites Rebudes en Web of Science: 13

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • *Bristol stool scale; *defecation; *stool

Campos d'Estudi

Projectes associats

ANALISIS DE NUEVOS GENES IMPLICADOS EN LA PATOGENESIS DE LA ENFERMEDAD CELIACA

Investigador Principal: CARMEN RIBES KONINCKX

PI02/0573 . INSTITUTO DE SALUD CARLOS III . 2004

INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP

Investigador Principal: CARMEN RIBES KONINCKX

643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015

NUEVA ESTRATEGIA PARA LA DERIVACIÓN DE HEPATOCITOS FUNCIONALES DE MUJERES AFECTAS DE DEFICIENCIA DE ORNITINA TRANSCARBAMILASA

Investigador Principal: BERNARDO ROQUE BORT MARTÍ

SAF2014-51991-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2015

UN REGISTRO NO INTERVENCIONISTA A LARGO PLAZO PARA EVALUAR LA SEGURIDAD Y EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES PEDIÁTRICOS CON ENFERMEDAD DE CROHN (EDC) ACTIVA ENTRE MODERADA Y GRAVE (CAPE).

Investigador Principal: ESTHER DONAT ALIAGA

P11-292 . 2015

ESTUDIO ABIERTO, MULTICÉNTRICO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV), CON O SIN DASABUVIR (DSV) Y CON O SIN RIBAVIRINA (RBV) EN PACIENTES PEDIÁTRICOS CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C (VHC) GENOTIPO 1 O 4 (ZIRCON).

Investigador Principal: CARMEN RIBES KONINCKX

M14-748 . 2016

ESTUDIO DE SEGURIDAD Y CAPACIDAD NUTRICIONAL DE UNA NUEVA FORMULA HIPOALERGICA PARA LACTANTES CON DIVERSAS FORMAS DE ALERGIA A LAS PROTEINAS DE LA LECHE DE VACA.

Investigador Principal: CARMEN RIBES KONINCKX

HER-FHT-2009-01 . 2010

A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 YEARS TO < 18 YEARS WITH FUNCTIONAL CONSTIPATION. / ESTUDIO MULTICENTRICO, ALEATORIZADO, CONTR OLADO CON PLACEBO Y CON DOBLE ANONIMATO (DOBLE CIEGO) DE LA EFICACIA, SEGURIDAD Y FARMACOCINETICA DE LA LUBIPROSTONA EN PACIENTES PEDIATRICOS CON EDAD . 6 ANOS Y < 18 ANOS CON ESTRENIMIENTO FUNCIONAL.

Investigador Principal: CARMEN RIBES KONINCKX

SAG/0211PFC-1131

A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION./ ESTUDIO MULTICÉNTRICO A LARGO PLAZO SOBRE LA SEGURIDAD, LA EFICACIA Y LA FARMACOCINÉTICA DE L UBIPROSTONA EN PACIENTES PEDIÁTRICOS DE EDADES COMPRENDIDAS ENTRE >= 6 AÑOS Y < 18 AÑOS CON ESTREÑIMIENTO FUNCIONAL.

Investigador Principal: CARMEN RIBES KONINCKX

SAG/0211PFC-11S1 . 2015

ESTUDIO FARMACOEPIDEMIOLÓGICO PARA ESTABLECER EL PERFIL DE SEGURIDAD A LARGO PLAZO DE TENOFOVIR DISOPROXIL FUMARATO (TENOFOVIR DF, VIREAD®) Y DESCRIBIR EL TRATAMIENTO DE LA TOXICIDAD RENAL Y ÓSEA ASOCIADA A TENOFOVIR DF EN ADOLESCENTES DE 12 A <18 AÑOS CO N HEPATITIS B CRÓNICA (HBC) EN EUROPA.

Investigador Principal: CARMEN RIBES KONINCKX

GS-EU-174-1403 . 2015

Compartir la publicació